{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-012996","form_type":"8-K","ticker":"DCTH","cik":"0000872912","company_name":"DELCATH SYSTEMS, INC.","filed_at":"2024-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.098378+00:00","generated_at":"2026-06-04T08:15:31.310238+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Delcath Systems reports Q4/FY2023 results; first HEPZATO KIT use, site guidance raised to 20","bullets":["First commercial HEPZATO KIT treatment for metastatic uveal melanoma performed at Moffitt Cancer Center.","Increased 2024 active treatment site guidance from 15 to 20 sites; three sites activated, four more imminent.","Product-specific J-code (J9248) and transitional pass-through payment effective April 1, 2024, from CMS.","Appointed Dr. Martha S. Rook as COO; raised $7.0M in private placement from insiders and existing investors.","Cash $32.5M at Dec 31, 2023; FY2023 revenue $2.1M (down from $2.7M); SG&A increased to $22.1M for commercial prep."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-012996","json":"https://secwatch.observer/filing/0001628280-24-012996.json","markdown":"https://secwatch.observer/filing/0001628280-24-012996.md","text":"https://secwatch.observer/filing/0001628280-24-012996.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872912/000162828024012996/0001628280-24-012996-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872912/000162828024012996/dcth-20240326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T08:15:31.310238+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f5b02291ff2f6dbf20bcf1e5723776005f8e9e59","claim":"DELCATH SYSTEMS, INC. reported fourth quarter and full year ended December 31, 2023 results: revenue approximately $0.5 million and $2.1 million, respectively. Guidance raised.","evidence_excerpt":"to year-end, on March 19, 2024, the company closed a $7.0 million private placement financing. Total revenue for the quarter and year-ended December 31, 2023, was approximately $0.5 million and $2.1 million, respectively, compared to $0.6 million and $2.7 million for the same periods in the prior year, respectively, from our sales of CHEMOSAT in Europe. Research and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/872912/000162828024012996/0001628280-24-012996-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"approximately $0.5 million and $2.1 million, respectively"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}